Accueil>>Lipids>> Glycerolipids>>(S)-Bromoenol lactone

(S)-Bromoenol lactone (Synonyms: (S)BEL)

Catalog No.GC40679

Le (S)-bromoénol lactone ((S)-BEL) est un inhibiteur irréversible, chiral, basé sur le mécanisme de la phospholipase A2β indépendante du calcium (iPLA2β) qui inhibe la libération d'arachidonate induite par la vasopressine À partir de culture de muscle lisse aortique de rat (A10) cellules avec une IC50 de 2 μM.

Products are for research use only. Not for human use. We do not sell to patients.

(S)-Bromoenol lactone Chemical Structure

Cas No.: 478288-94-7

Taille Prix Stock Qté
500μg
43,00 $US
En stock
1mg
77,00 $US
En stock
5mg
321,00 $US
En stock
10mg
514,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The phospholipases are an extensive family of lipid hydrolases that function in cell signaling, digestion, membrane remodeling, and as venom components. The calcium-independent phospholipases (iPLA2) are a PLA2 subfamily closely associated with the release of arachidonic acid in response to physiologic stimuli. (S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase β (iPLA2β) that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC50 value of 2 µM. (S)-BEL is more than 1,000-fold selective for iPLA2 versus cPLA2, and is 10-fold selective for iPLA2β versus iPLA2γ.

Avis

Review for (S)-Bromoenol lactone

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (S)-Bromoenol lactone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.